BMS halts hep C trial after 'serious safety issue'
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has suspended a Phase II study of its experimental hepatitis C drug BMS-094 because of "a serious safety issue". BMS-094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor, was the driver behind BMS' $2.5 billion acquisition of Inhibitex at the start of this year (scripintelligence.com, 9 January 2012).